Table 2 Genotype distributions of three SNPs in IL16 between osteosarcoma patients and controls.
From: Association of interleukin 16 gene polymorphisms and plasma IL16 level with osteosarcoma risk
Polymorphisms | Osteosarcoma patients, n = 358 (%) | Controls, n = 402 (%) | Crude OR | Adjusted OR (95% CI)† | Adjusted P value† |
|---|---|---|---|---|---|
rs4778889 | |||||
TT | 215 (60.1) | 240 (59.7) | 1.00 (Ref) | 1.00 (Ref) | |
TC | 127 (35.5) | 140 (34.8) | 1.01 (0.75–1.37) | 1.01 (0.75–1.37) | 0.94 |
CC | 16 (4.5) | 22 (5.5) | 0.81 (0.42–1.59) | 0.81 (0.41–1.60) | 0.55 |
Dominant | 0.99 (0.74–1.32) | 0.99 (0.74–1.32) | 0.92 | ||
Recessive | 0.81 (0.42–1.56) | 0.81 (0.42–1.57) | 0.53 | ||
rs11556218 | |||||
TT | 165 (46.1) | 235 (58.5) | 1.00 (Ref) | 1.00 (Ref) | |
TG | 174 (48.6) | 151 (37.6) | 1.64 (1.22–2.20) | 1.65 (1.23–2.21) | <0.001 |
GG | 19 (5.3) | 16 (4.0) | 1.69 (0.84–3.39) | 1.69 (0.84–3.40) | 0.14 |
Dominant | 1.65 (1.23–2.19) | 1.66 (1.24–2.21) | <0.001 | ||
Recessive | 1.35 (0.68–2.67) | 1.39 (0.70–2.77) | 0.34 | ||
rs4072111 | |||||
CC | 218 (60.9) | 229 (57.0) | 1.00 (Ref) | 1.00 (Ref) | |
CT | 124 (34.6) | 158 (39.3) | 0.82 (0.61–1.11) | 0.82 (0.61–1.11) | 0.19 |
TT | 16 (4.5) | 15 (3.7) | 1.12 (0.54–2.32) | 1.12 (0.54–2.33) | 0.75 |
Dominant | 0.85 (0.64–1.14) | 0.85 (0.63–1.13) | 0.26 | ||
Recessive | 1.21 (0.59–2.48) | 1.22 (0.60–2.52) | 0.58 | ||
